Stocks mixed...Trade talks with Canada resume...Google skips hearing on social media practices
NEW YORK (AP) — Stocks are mixed as technology companies take a second day of losses. Consumer-focused companies are also declining, while traditionally defensive companies are faring better. The Dow Jones industrial average was up slightly in afternoon trading, while the S&P 500 and the Nasdaq were falling.
WASHINGTON (AP) — Trump administration officials and Canadian negotiators are resuming talks aimed at keeping Canada in a North American trade bloc with the United States and Mexico. Canadian Foreign Affairs Minister Chrystia Freeland is meeting in Washington with U.S. Trade Rep. Robert Lighthizer (LYT’-hy-zur). Last week, the United States and Mexico reached a preliminary agreement to replace the 24-year-old North American Free Trade Agreement. But those talks excluded Canada, the third NAFTA country.
WASHINGTON (AP) — Google has skipped a Senate intelligence hearing on efforts by social media companies to prevent disinformation and election meddling. Florida Republican Marco Rubio says Google executives are trying to avoid answering the kind of questions raised in a report by a watchdog group. The group was able to buy ads while posing as Russia’s Internet Research Agency, the propaganda machine accused of interfering in the 2016 U.S. election.
NEW YORK (AP) — Amazon says it has ordered 20,000 vans for its new delivery program, which invites contractors to launch delivery businesses for the online retailer. Amazon says “tens of thousands” of people have applied for the program. The vans featuring Amazon’s blue smile log will be built at a new Mercedes-Benz plant in South Carolina.
UNDATED (AP) — A company whose opioid marketing practices are being blamed for sparking a nationwide addiction crisis is helping to fund an effort to make a lower-cost overdose antidote. OxyContin maker Purdue Pharma says it’s making a $3.4 million grant to Harm Reduction Therapeutics, a Pittsburgh-based nonprofit, to help develop a low-cost naloxone (nuh-LAHKS’-ohn) nasal spray. Harm Reduction Therapeutics says it is trying to get its version to the market within two years.